Investigating and Comparing the Effects of Vasopressin Injection around Uterine Myoma and Rectal Misoprostol Injection in open Myomectomy Surgery to Reduce Bleeding: A Randomized Interventional Study
DOI:
https://doi.org/10.61841/8cg57s13Keywords:
Vasopressin, Misoprostol, MyomectomyAbstract
The objective of this study was to compare the effects of vasopressin injection around the uterine myoma in open myomectomy with misoprostol rectal surgery to reduce bleeding during the surgery and the level of changes in hemoglobin. In a clinical trial study, 66 patients who were candidates for open myomectomy were randomly divided into two groups (each group included 33 patients). The first group received 400 µg of misoprostol 30 minutes before rectal surgery, and the second group received a 20-unit vasopressin ampoule in 19 ml of dissolved normal saline 30 minutes before the surgery. The bleeding volume and hemoglobin level before and after the surgery were measured in two groups and compared with independent and paired t-tests. The mean bleeding volume in the two misoprostol and vasopressin groups was 199.4 ± 370.9 and 261.5 ± 120.3 ml, respectively. The mean lost blood was lower in the vasopressin group (p=0.009). The mean changes in hemoglobin level in the misoprostol and vasopressin groups were 1.68 ± 0.63 and 1.3 ± 0.55 g / dl, respectively, and the difference between two groups was significant (p = 0.01). Based on the results of our study, vasopressin seems to be more effective than misoprostol in controlling bleeding during myomectomy, but due to inconsistencies in the results of different studies, further studies on these two drugs are recommended to determine the most effective drug in controlling bleeding during the myomectomy surgery.
Downloads
References
1. Zaloudek CJ, Hendrickson MR, Soslow RA. Mesenchymal tumors of the uterus. Blaustein’s pathology of
the female genital tract. 2011:453-527.
2. Kongnyuy EJ, Wiysonge CS. Intervention to reduce hemorrhage during myomectomy for fibroids.
Cochrane Database syst Rv.2014; 15:8CD005355-58
3. Day Baird D, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine
leiomyoma in Black and white women: ultrasound evidence. Am J Obstet Gynecol 2003; 188: 100–7.
4. Saadatnia G, Saremi A, Salehian B, Salehian P. Uterine Leiomyoma and Reproductive Tract Infections
Detected by polymerase chain reaction. Iranian Journal of Pathology. 2019 Jan 1; 14(1):15-17
5. Goodwin SC, Spies JB, Worthington-Kirsch R, Peterson E, Pron G, Li S, et al.Uterine artery Embolization
for treatment of leiomyomata: long-term outcomes from the fibroid registry. Obstet Gynecol 2008; 111:22–
3.
6. Tulandi T, Salamah K. Fertility and uterine artery embolization. Obstet Gynecol 2010;115:857–60.
7. Kim CH, Kim SR, Lee HA, Kim SH, Chae HD, Kang BM. Transvaginal ultrasound-guided radiofrequency
myolysis for uterine myomas. Hum Re-prod 2012; 26:559–63.
8. Dubuisson J, Fauconnier A, Deffarges J, Norgaard C, Kreiker G, Chapron C.Pregnancy outcome and
deliveries following laparoscopic myomectomy.Hum Reprod 2000;15:869–73.
9. Neilson JP. Interventions to reduce haemorrhage during myomectomy for fibroids [Comment on Kongnyuy
EJ, Wiysonge CS. Cochrane Database Syst Rev 2007; 1: CD005355.]. Obstet Gynecol 2007; 109: 1197–8.
10. 10. Alyssa W, Chun C, Sik Y.Transcervical intralesional vasopressin injection compared with placebo in
hysteroscopic myomectomy.The American College of Obstetricians and Gynecologists, 2014; 897-903.
11. Protopapas A, Giannoulis G, Chatzipapas I, Athanasiou S, Grigoriadis T, Kathopoulis N, Vlachos DE,
Zaharakis D, Loutradis D. Vasopressin during Laparoscopic Myomectomy: Does It Really Extend Its
Limits?. Journal of minimally invasive gynecology. 2019 Mar 1; 26(3):441-9.
12. Agostini A, RondaI, Franchi F, Ronda B, Ludovic RC, Bernard B. Oxytocin during myomectomy: a
randomized study. Eur J Obstet Gynecol Reprod Biol; 2005; 118:235–8.
13. Samanta S, Samanta S, Jain K, Chatterjee D. Intramyometrial terlipressin in atonic postpartum hemorrhage:
A uterine salvage decision. Anaesthesia, Pain & Intensive Care. 2019 May 20.
14. Taylor A, Sharma M, Tsirkas P, Di Spiezio Sardo A, Setchell M, Magos A.Reducing blood loss at open
myomectomy using triple tourniquets: a randomized controlled trial. Int J Gynecol Obstet 2005; 112:340–5.
15. Benassi L, Lopopolo G, Pazzoni F, Ricci L, Kaihura C, Piazza F, et al. Chemically assisted dissection of tissues: an interesting support in abdominal myomectomy. J Am Coll Surg 2000; 191: 65–9.
16. Zullo F, Palomba S, Corea D, Pellicano M, Russo T, Falbo A, et al. Bupivacaineplus epinephrine for
Laparoscopic myomectomy: a randomized placebo-controlled trial. Obstet Gynecol 2004; 104:243–9.
17. Chen C. Laparoscopic myomectomy for large myomas. Int Surg 2006; 91(Suppl):S77–80.
18. Jonathan S. Berek and Novaks Gynecology. 15th edition 2012; vol. 1:423-40.
19. SinhaR, Sundaram M,Lakhotia S,Mahajan C, RajeS,KadamP,RaoG.Lapa-roscopic myomectomy with
Uterine artery ligation: review article and comparative analysis. J Gynecol Endosc Surg 2012; 2:3–10.
20. Elsheikh A, Antsaklis A, Mesogitis S, Papantoniou N, Rodolakis A, Vogas E,et al. Use of misoprostol for
the termination of second trimester pregnan-cies. Arch Gynecol Obstet 2001; 265:204–6.
21. Bugalho A, Daniel A, Faundes A, Cunha M. Misoprostol for prevention of postpartum hemorrhage. Int J
Gynaecol Obstet 2001; 73:16.
22. Muhammad R, Isah A, Agida T, Akaba G. A prospective study to compare the effectiveness of adjunctive
rectal misoprostol or oxytocin titration in the prevention of primary post-partum haemorrhage in at-risk
patients. African health sciences. 2019; 19(1):1517-24.
23. Celik H, Sapmaz E. Use of a single preoperative dose of misoprostol is efficacious for patients who undergo
abdominal myomectomy. Fertil Steril2003; 79:1207–10
24. Sharifa F, Joseph F, Horance F.A trial comparing the use of rectal misoprostol plus perivascular vasopressin
alone to decrease myometrial bleeding at the time of abdominal myomectomy. Fertility and Sterility 2013;
vol. 100: 1044-49.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 AUTHOR
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
